<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lee I</submitter><funding>NIH/NINDS</funding><funding>NINDS NIH HHS</funding><pagination>175-179</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11891797</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>26(1-2)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>A high glycemic index and high glycemic load diet has been associated with slower progression of amyotrophic lateral sclerosis (ALS), suggesting a benefit from high blood glucose levels. We examined the association between average blood glucose level and ALS progression in two independent cohorts.&lt;h4>Methods&lt;/h4>Sporadic ALS patients enrolled in the ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS) who completed a 3-month follow-up visit and had available blood samples were included. Hemoglobin A1c (HbA1c) was measured from whole blood collected at the 3-month follow-up. From the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database, we included ALS patients with one or more HbA1c measurements at enrollment and available death information. Associations between HbA1c with revised ALS functional rating scale (ALSFRS-R)/ALSFRS total score change, and tracheostomy-free survival/survival were examined in these cohorts using linear regression, linear mixed-effects models, and Cox proportional hazard models, adjusted for covariates.&lt;h4>Results&lt;/h4>In the ALS COSMOS cohort (&lt;i>n&lt;/i> = 193), HbA1c level was not significantly associated with the change in the ALSFRS-R total score from baseline to the 3-month follow-up (&lt;i>p&lt;/i> = 0.8) nor baseline to the 6-month follow-up (&lt;i>p&lt;/i> = 0.4). No significant association was found between HbA1c level and tracheostomy-free survival (&lt;i>p&lt;/i> = 0.8). In the PRO-ACT cohort (&lt;i>n&lt;/i> = 928), no significant association was found between HbA1c level and the rate of ALSFRS decline in the first 200 days (&lt;i>p&lt;/i> = 0.81 for interaction) nor between HbA1c level and survival (&lt;i>p&lt;/i> = 0.45).&lt;h4>Interpretation&lt;/h4>We did not find convincing evidence that mean blood glucose level is associated with disease progression among ALS patients.</pubmed_abstract><journal>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</journal><pubmed_title>Blood glycated hemoglobin level is not associated with disease progression in amyotrophic lateral sclerosis.</pubmed_title><pmcid>PMC11891797</pmcid><funding_grant_id>K23 NS131586</funding_grant_id><funding_grant_id>K23NS131582</funding_grant_id><pubmed_authors>Rosenbaum M</pubmed_authors><pubmed_authors>Vestrucci M</pubmed_authors><pubmed_authors>Lee S</pubmed_authors><pubmed_authors>Mitsumoto H</pubmed_authors><pubmed_authors>Lee I</pubmed_authors></additional><is_claimable>false</is_claimable><name>Blood glycated hemoglobin level is not associated with disease progression in amyotrophic lateral sclerosis.</name><description>&lt;h4>Objective&lt;/h4>A high glycemic index and high glycemic load diet has been associated with slower progression of amyotrophic lateral sclerosis (ALS), suggesting a benefit from high blood glucose levels. We examined the association between average blood glucose level and ALS progression in two independent cohorts.&lt;h4>Methods&lt;/h4>Sporadic ALS patients enrolled in the ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS) who completed a 3-month follow-up visit and had available blood samples were included. Hemoglobin A1c (HbA1c) was measured from whole blood collected at the 3-month follow-up. From the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database, we included ALS patients with one or more HbA1c measurements at enrollment and available death information. Associations between HbA1c with revised ALS functional rating scale (ALSFRS-R)/ALSFRS total score change, and tracheostomy-free survival/survival were examined in these cohorts using linear regression, linear mixed-effects models, and Cox proportional hazard models, adjusted for covariates.&lt;h4>Results&lt;/h4>In the ALS COSMOS cohort (&lt;i>n&lt;/i> = 193), HbA1c level was not significantly associated with the change in the ALSFRS-R total score from baseline to the 3-month follow-up (&lt;i>p&lt;/i> = 0.8) nor baseline to the 6-month follow-up (&lt;i>p&lt;/i> = 0.4). No significant association was found between HbA1c level and tracheostomy-free survival (&lt;i>p&lt;/i> = 0.8). In the PRO-ACT cohort (&lt;i>n&lt;/i> = 928), no significant association was found between HbA1c level and the rate of ALSFRS decline in the first 200 days (&lt;i>p&lt;/i> = 0.81 for interaction) nor between HbA1c level and survival (&lt;i>p&lt;/i> = 0.45).&lt;h4>Interpretation&lt;/h4>We did not find convincing evidence that mean blood glucose level is associated with disease progression among ALS patients.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Feb</publication><modification>2026-06-17T04:52:43.49Z</modification><creation>2026-06-17T03:07:54.117Z</creation></dates><accession>S-EPMC11891797</accession><cross_references><pubmed>39329381</pubmed><doi>10.1080/21678421.2024.2407409</doi></cross_references></HashMap>